You are here:

omalizumab 150mg powder and solvent for injection (Xolair)

Advice

Following a second re-submission.

Omalizumab (Xolair®) is accepted for restricted use within NHS Scotland as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe persistent allergic asthma. It is restricted to initiation and monitoring by hospital physicians experienced in the diagnosis and treatment of severe persistent asthma.

It is restricted to patients who are prescribed chronic systemic steroids and in whom all other treatments have failed. The response to omalizumab treatment should be assessed in all patients at 16 weeks and treatment should be discontinued in patients who have not shown a marked improvement in overall asthma control.

Drug Details

Drug Name: omalizumab 150mg powder and solvent for injection (Xolair)
SMC Drug ID: 259/06
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Asthma
BNF Category:
Submission Type: Resubmission
Status: Superseded
Date Advice Published: 8 October 2007

Archived Advice

Resubmission 15 January 2007
Full submission 12 June 2006

Back